Esperion Therapeutics Inc.

NASDAQ:ESPR   3:59:51 PM EDT
6.85
+0.18 (+2.70%)
Earnings Announcements

Esperion Reports Second Quarter 2022 Financial Results

Published: 08/02/2022 11:35 GMT
Esperion Therapeutics Inc. (ESPR) - Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update.
Q2 Loss per Share $1.05.
Expects Full-year 2022 Operating Expenses to Be Approximately $220 Million to $240 Million.
Total Revenue for Q2 Ended June 30, 2022, Was $18.8 Million.
Q2 Earnings per Share View $-0.93, Revenue View $18.7 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $19.53 Million
Adjusted EPS is expected to be -$0.93

Next Quarter Revenue Guidance is expected to be $21.74 Million
Next Quarter EPS Guidance is expected to be -$0.89

More details on our Analysts Page.